1. Home
  2. SBLX vs ARTL Comparison

SBLX vs ARTL Comparison

Compare SBLX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBLX

StableX Technologies Inc.

N/A

Current Price

$3.35

Market Cap

3.8M

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.85

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBLX
ARTL
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBLX
ARTL
Price
$3.35
$1.85
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
110.3K
1.2M
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$1.52
52 Week High
$15.28
$28.60

Technical Indicators

Market Signals
Indicator
SBLX
ARTL
Relative Strength Index (RSI) 46.29 39.37
Support Level $2.68 $1.69
Resistance Level $4.00 $2.08
Average True Range (ATR) 0.49 0.21
MACD 0.11 0.10
Stochastic Oscillator 42.65 58.88

Price Performance

Historical Comparison
SBLX
ARTL

About SBLX StableX Technologies Inc.

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: